Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 5Completed 4Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 12Gastrointestinal 5Genitourinary 4Tumor-Agnostic 3Head & Neck 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Classical hematology 1CNS 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × abemaciclib × Tumor-Agnostic × Clear all
NCT04534283 2024-08-07

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Indiana University

Phase 2 Terminated
16 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03997448 2024-02-20

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Big Ten Cancer Research Consortium

Phase 2 Terminated
3 enrolled 10 charts
Tumor-Agnostic

Adenocarcinoma

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡